Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

Ratios

Enanta Pharmaceuticals (ENTA) Shares Issued (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Shares Issued readings, the most recent being $69.9 million for Q4 2025.

On a quarterly basis, Shares Issued rose 74312.77% to $69.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $70.0 million, a 28945.23% increase, with the full-year FY2025 number at $145000.0, down 1.36% from a year prior.
Shares Issued hit $69.9 million in Q4 2025 for Enanta Pharmaceuticals, up from $51000.0 in the prior quarter.
In the past five years, Shares Issued ranged from a high of $69.9 million in Q4 2025 to a low of $28000.0 in Q2 2024.
Median Shares Issued over the past 5 years was $912500.0 (2021), compared with a mean of $6.0 million.
Biggest five-year swings in Shares Issued: tumbled 95.15% in 2023 and later skyrocketed 74312.77% in 2025.
Enanta Pharmaceuticals' Shares Issued stood at $10.4 million in 2021, then crashed by 89.18% to $1.1 million in 2022, then crashed by 82.24% to $200000.0 in 2023, then crashed by 53.0% to $94000.0 in 2024, then skyrocketed by 74312.77% to $69.9 million in 2025.
The last three reported values for Shares Issued were $69.9 million (Q4 2025), $51000.0 (Q3 2025), and $94000.0 (Q4 2024) per Business Quant data.